Sana Biotechnology (SANA) Common Equity (2020 - 2026)
Sana Biotechnology (SANA) posted Common Equity of $119.2 million for Q1 2026, down 25.88% sequentially from $160.9 million in Q4 2025, and down 42.97% YoY from $209.1 million in Q1 2025.
Sana Biotechnology (SANA) Common Equity (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported Common Equity for 7 years, with the latest figure at $119.2 million in Q1 2026.
- Quarterly Common Equity fell 42.97% year-over-year to $119.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.2 million (down 42.97% YoY) and the FY2025 annual result came in at $160.9 million, down 35.78% from the prior year.
- Common Equity slipped to $119.2 million in Q1 2026 per SANA's latest filing, from $160.9 million in the prior quarter.
- Over five years, Common Equity peaked at $701.7 million in Q1 2022 and troughed at $119.2 million in Q1 2026.
- A 5-year average of $347.5 million and a median of $339.6 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity dropped 4.33% in 2024, then plunged 63.92% in 2025.
- Over 5 years, Common Equity stood at $499.3 million in 2022, then tumbled by 42.42% to $287.5 million in 2023, then retreated by 12.87% to $250.5 million in 2024, then plunged by 35.78% to $160.9 million in 2025, then decreased by 25.88% to $119.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $119.2 million, $160.9 million, and $195.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - | 154.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 154.57 Mn |
| Mar 31, 2026 | 119.24 Mn |
| Dec 31, 2025 | 160.88 Mn |
| Sep 30, 2025 | 195.31 Mn |
| Jun 30, 2025 | 122.56 Mn |
| Mar 31, 2025 | 209.08 Mn |
| Dec 31, 2024 | 250.50 Mn |
| Sep 30, 2024 | 292.48 Mn |
| Jun 30, 2024 | 339.65 Mn |
| Mar 31, 2024 | 375.14 Mn |
| Dec 31, 2023 | 287.51 Mn |
| Sep 30, 2023 | 365.85 Mn |
| Jun 30, 2023 | 355.03 Mn |
| Mar 31, 2023 | 428.26 Mn |
| Dec 31, 2022 | 499.32 Mn |
| Sep 30, 2022 | 566.02 Mn |
| Jun 30, 2022 | 639.51 Mn |
| Mar 31, 2022 | 701.66 Mn |
| Dec 31, 2021 | 728.50 Mn |
| Sep 30, 2021 | 830.09 Mn |